Evidence map›Paper›PMID 40025449›Full record

ArticleBMC pediatrics2025

Procalcitonin use in febrile children attending European emergency departments: a prospective multicenter study.

Dorine M Borensztajn, Joany M Zachariasse, Enitan D Carrol, Ruud G Nijman, Ulrich von Both, Marieke Emonts, Jethro Herberg, Benno Kohlmaier, Michael Levin, Emma Lim and 12 more

Abstract readMulticenter StudyComparative Study
In one paragraph

Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Dorine M BorensztajnDepartment of General Pediatrics, Erasmus MC-Sophia Children's Hospital, Wytemaweg 80, Rotterdam, 3015 CN, the Netherlands. dm.borensztajn@nwz.nl.
Joany M ZachariasseDepartment of General Pediatrics, Erasmus MC-Sophia Children's Hospital, Wytemaweg 80, Rotterdam, 3015 CN, the Netherlands.
Enitan D CarrolDepartment of Clinical Infection, Microbiology and Immunology, Institute of Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Ruud G NijmanImperial College of Science, Technology and Medicine, Section of Pediatric Infectious Diseases, London, UK.
Ulrich von BothDr. Von Hauner Children's Hospital, Division of Pediatric Infectious Diseases, University Hospital, Ludwig-Maximilians-University (LMU), München, Germany.
Marieke EmontsNewcastle upon Tyne NHS Hospitals Foundation Trust, Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy; and Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, UK.
Jethro HerbergImperial College of Science, Technology and Medicine, Section of Pediatric Infectious Diseases, London, UK.
Benno KohlmaierDepartment of General Pediatrics, Medical University of Graz, Graz, Austria.
Michael LevinImperial College of Science, Technology and Medicine, Section of Pediatric Infectious Diseases, London, UK.
Emma LimNewcastle upon Tyne NHS Hospitals Foundation Trust, Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy; and Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, UK.
Ian K MaconochieImperial College of Science, Technology and Medicine, Section of Pediatric Infectious Diseases, London, UK.
Federico Martinón-TorresHospital Clínico Universitario de Santiago de Compostela, Genetics, Vaccines, Infections and Pediatrics Research group (GENVIP), Santiago de Compostela, Spain.
Marko PokornDepartment of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Irene Rivero-CalleHospital Clínico Universitario de Santiago de Compostela, Genetics, Vaccines, Infections and Pediatrics Research group (GENVIP), Santiago de Compostela, Spain.
Aleksandra RudzāteDepartment of Pediatrics, Rīgas Stradiņa Universitāte, Children Clinical University Hospital, Riga, Latvia.
Chantal D TanDepartment of General Pediatrics, Erasmus MC-Sophia Children's Hospital, Wytemaweg 80, Rotterdam, 3015 CN, the Netherlands.
Maria TsoliaSecond Department of Pediatrics, National and Kapodistrian University of Athens, P. And A. Kyriakou Children'S Hospital, Athens, Greece.
Clementien VermontDepartment of Pediatric Infectious Diseases & Immunology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Dace ZavadskaDepartment of Pediatrics, Rīgas Stradiņa Universitāte, Children Clinical University Hospital, Riga, Latvia.
Werner ZenzDepartment of General Pediatrics, Medical University of Graz, Graz, Austria.
Henriette A MollDepartment of General Pediatrics, Erasmus MC-Sophia Children's Hospital, Wytemaweg 80, Rotterdam, 3015 CN, the Netherlands.
PERFORM consortium: Personalised Risk assessment in febrile children to optimise Real-life Management across the European Union

Funding

European Union's Horizon 2020 research and innovation program 668303, 848196
6 · The paper itself

Abstract

backgroundStudies on procalcitonin (PCT) for identifying sepsis were published as early as 1993 and since then, PCT has been the topic of over 8,500 studies. Several studies show PCT to be superior to CRP in differentiating invasive infections such as sepsis from viral infections, especially early in the disease course. However, its actual use in clinical practice is poorly documented. Our aim was to study the use of PCT in febrile children attending the ED across Europe and compare this to the use of CRP.

methodsThe MOFICHE/PERFORM study, a prospective multicenter study, took place at 12 European EDs in eight countries and included febrile children < 18 years. In this secondary analysis of nine participating EDs that used PCT, descriptive analyses were performed, describing the use of PCT in all febrile children and for different age groups, foci of fever and fever duration.

resultsIn total, 31,612 pediatric febrile episodes were available for analyses. Blood tests were performed in 15,812 (50.0%, range 9.6-92.6%)) febrile episodes. CRP was included in 98.3% of blood tests (range between hospitals 80-100%), while PCT was included in only 3.9% (range 0.1-86%). PCT was most often performed in children below 3 months (12.0% versus 3.6% in older children, p < 0.001). PCT was used slightly more often in children with fever less than 24 h in comparison to children with a duration of fever ≥ 24 h (4.9% versus 3.4%, p < 0.001). Regarding clinical alarming signs, PCT was used most often in children with meningeal signs (7.0%) or a non-blanching rash (10.9%).

conclusionActual PCT use in febrile children at European EDs is limited and varies largely between hospitals. Possible explanations include lack of guidelines, limited availability, higher costs and lack of readiness to adapt new clinical strategies.

Indexed as

Emergency Service, HospitalFeverProcalcitoninSepsisAdolescentBiomarkersChildChild, PreschoolC-Reactive ProteinEuropeFemaleHumansInfantInfant, NewbornMaleProspective StudiesBiomarkersC-Reactive ProteinProcalcitoninBiomarkersCRPEmergency DepartmentProcalcitonin

Identifiers

PMID40025449
PMCPMC11871781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.